+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schistosomiasis - Pipeline Review, H2 2019

  • ID: 4866523
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 37 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • IRBM Science Park SpA
  • Knight Therapeutics Inc
  • Merck KGaA
  • Pai Life Sciences Inc
  • Tongli Biomedical Co Ltd
  • MORE
Schistosomiasis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2019, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.

Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Schistosomiasis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • IRBM Science Park SpA
  • Knight Therapeutics Inc
  • Merck KGaA
  • Pai Life Sciences Inc
  • Tongli Biomedical Co Ltd
  • MORE
Introduction
Report Coverage
Schistosomiasis - Overview
Schistosomiasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Schistosomiasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Schistosomiasis - Companies Involved in Therapeutics Development
Ebelle Pharmaceuticals Inc
IRBM Science Park SpA
Knight Therapeutics Inc
Merck KGaA
Pai Life Sciences Inc
Tongli Biomedical Co Ltd
Schistosomiasis - Drug Profiles
EDE-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
intestinal schistosomiasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-Praziquantel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miltefosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
praziquantel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-praziquantel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
schistosomiasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Schistosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Schistosomiasis - Dormant Projects
Schistosomiasis - Product Development Milestones
Featured News & Press Releases
Jan 18, 2018: George Washington University: Schistosoma vaccine to enter phase Ib clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Schistosomiasis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Schistosomiasis - Pipeline by Ebelle Pharmaceuticals Inc, H2 2019
Table 11: Schistosomiasis - Pipeline by IRBM Science Park SpA, H2 2019
Table 12: Schistosomiasis - Pipeline by Knight Therapeutics Inc, H2 2019
Table 13: Schistosomiasis - Pipeline by Merck KGaA, H2 2019
Table 14: Schistosomiasis - Pipeline by Pai Life Sciences Inc, H2 2019
Table 15: Schistosomiasis - Pipeline by Tongli Biomedical Co Ltd, H2 2019
Table 16: Schistosomiasis - Dormant Projects, H2 2019

List of Figures
Figure 1: Number of Products under Development for Schistosomiasis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ebelle Pharmaceuticals Inc
  • IRBM Science Park SpA
  • Knight Therapeutics Inc
  • Merck KGaA
  • Pai Life Sciences Inc
  • Tongli Biomedical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll